Isomorphic Labs, an AI company focussed on designing and developing new medicines, today announced a €4.5 billion ($5 billion) Series C financing round to accelerate the scientific breakthroughs and proprietary AI advances.
The round was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz, with continued significant investment from Alphabet. The round also included participation from all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.
“When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI,” says Sir Demis Hassabis, founder and CEO of Isomorphic Labs. “Our drug design engine is generating molecules with unprecedented precision and speed. This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”
The announcement comes amid several other European investments in AI-enabled drug discovery and pharmaceutical research during 2026 – although nowhere near as large.
In the UK, London-based Helical raised €8.4 million for its virtual AI laboratory, Ternary Therapeutics secured €4.1 million for AI-designed molecular glues, and Sable Bio attracted €3.15 million for its drug-safety platform.
Elsewhere, France’s Orakl Oncology raised €30 million and Rivercell secured €22 million, while Switzerland’s Adaptyv Bio announced €34.35 million for automated biological testing.
Together with other relevant rounds involving WhiteLab Genomics, Generare and Sightera Biosciences, these financings represent approximately €148.2 million in 2026 funding reported by EU-Startups, excluding Isomorphic Labs.
EU-Startups also previously covered Isomorphic Labs’ €1.8 billion Series B among the major UK technology financings of the first half of 2026.
“Isomorphic Labs is building foundational technology for the future of medicine,” adds Konstantine Buhler, Partner at Sequoia Capital. “It’s inspiring to see the Isomorphic team translate advanced AI into a growing portfolio of drug candidates. Using AI to improve human health is one of the most important challenges of our generation. We’re proud to co-lead this round and help further scientific discovery in medicine.”
Isomorphic Labs was founded in 2021, the company has built a world-leading AI drug design engine comprising foundational AI models that are capable of working across multiple therapeutic areas and drug modalities.
Isomorphic is scaling its proprietary drug design engine (IsoDDE) and therapeutic candidate pipeline designed with AI to deliver the next generation of medicines. IsoDDE unifies a suite of foundational simulation AI models that natively work across multiple therapeutic areas and drug modalities.
IsoDDE explores vast chemical spaces to design, refine, and deliver engineered molecules with optimal drug-like properties.
The company outlines that the breadth and precision of the simulation models within IsoDDE push predictions towards experimental accuracy and provide a suite of capabilities to advance innovative medicines. Combined with powerful proprietary agents that navigate and reason over highly complex biological systems, these models directly and repeatedly translate into advancements across the company’s multi-modality pipeline of therapeutic candidates, addressing some of the most challenging problems in the industry.
“Every week we are making repeatable scientific advancements enabled by our models,” says Max Jaderberg, President of Isomorphic Labs. “These translate directly into better molecular profiles with the potential to be new medicines and unlock some of the hardest problems in drug discovery. Our interdisciplinary teams combine world-leading machine learning researchers with top-class drug hunters and together they are routinely solving complex biological problems that have stalled traditional research for decades.
“We are translating our discoveries directly into potential life-changing medicines, built on the infrastructure we are establishing for the future of bioengineering with this investor backing.”
Today’s capital will continue to mature IsoDDE as well as expand deeper into new biology with highly advanced models. To deliver new and transformative classes of therapeutics, Isomorphic is creating a partner ecosystem to advance the understanding of mechanistic disease biology. In parallel, the company is building the global infrastructure required to power the future of AI-led bioengineering.
Proceeds will also support the company’s continued build of scalable AI-first translational and clinical development infrastructure as it advances its drug candidates to clinical trials.
